Dear Blood Donors, You've Given Me the Gift of Life I offer my gratitude through acceptance, acknowledgement, and reflection Feb 06, 2022
FDA Concerned About Safety of Lymphoma Drug Hint of excess mortality in trial of umbralisib/ublituximab prompts public notice Feb 03, 2022
Finally, a 'New Standard' for Severe Aplastic Anemia After 3 decades of failures, RACE trial shows superiority of new first-line regimen Jan 05, 2022
Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survival Disease characteristics, prognostic factors similar to those of older patients Jan 04, 2022
Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemia OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy Dec 17, 2021
Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLL Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease Dec 16, 2021
Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphoma Updated analysis confirms advantages of less aggressive approach to low-burden disease Dec 16, 2021
Gene Therapy Resolves Severe Pain Events in Sickle Cell Disease LentiGlobin also normalized hemoglobin and reduced hemolysis markers Dec 15, 2021
Can Dasatinib Dose Be Halved in Low-Risk CML? Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCL Patients, trial design, logistics among possible explanations for lack of EFS benefit Dec 14, 2021
Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/B Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors Dec 14, 2021
R-CHOP Toppled in First-Line DLBCL Trial Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALL One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
Ξ²-Thalassemia Patients Go Transfusion-Free With Gene Therapy Treatment with beti-cel is "potentially curative" in this transfusion-dependent group Dec 13, 2021
R2 Maintenance for Elderly MCL Patients Worth the Risk? Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphoma Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
Next-Gen MRD Testing Predicts Acute Leukemia Relapse After CAR-T Nearly all patients with detectable disease relapsed or progressed to transplant, other therapies Dec 01, 2021
Chemo-Free Regimen Highly Active in Older Mantle Cell Lymphoma Patients Overall response rate of 96% with ibrutinib-rituximab, but cardiotoxicity a possible issue Nov 29, 2021
Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patients Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
Pegylated Interferon Wins FDA Approval for Polycythemia Vera Majority of patients attained complete hematologic response with ropeginterferon alfa-2b Nov 15, 2021
Is Multiple Myeloma a Greater Threat to Black Patients? Incidence and treatment disparities combined with a heightened COVID risk is cause for concern Nov 11, 2021
A Gentler Standard for Acute Promyelocytic Leukemia in Kids ATRA/arsenic trioxide without maintenance therapy resulted in 99-100% survival at 2 years Nov 11, 2021
Vaccinated Blood Cancer Patients Still at Risk for Severe COVID-19 Those with hematologic malignancies also remain at higher risk of mortality as well Nov 08, 2021
Ibrutinib Boosts Survival in Younger Patients With Certain DLBCL Subtypes New analysis "casts the PHOENIX trial in a new light," authors say Nov 04, 2021
FDA Approves STAMP Inhibitor for Chronic Myeloid Leukemia Patients treated with two or more TKIs and those with T315I mutation gain new option Nov 01, 2021
Ibrutinib-Rituximab Wins Out in Waldenstrom's Macroglobulinemia Risk of disease progression or death reduced by 75% versus rituximab alone Oct 11, 2021
Longer Hydroxyurea Tied to Improved Sickle-Cell Heart Issues Kids on treatment for less than 1 year had a significantly greater prevalence of LV dilation Sep 16, 2021
9/11 Responders Face Higher Risk of Multiple Cancers Longer follow-up sheds light on the long-term consequences of exposure to disaster site Sep 10, 2021
Life Expectancy Still Lower for Blood or Marrow Transplant Recipients Although late mortality has decreased over the past 40 years Sep 09, 2021
Liver Toxicity in Gene Therapy Trials Could Merit Stricter Entry Criteria FDA panel weighs in on lower vector doses and role of animal studies Sep 03, 2021
Adding Mycophenolate Mofetil Improves Outcomes in ITP "Somewhat decreased" quality of life, however, British study finds Sep 01, 2021
Non-Chemo Regimen Highly Active in R/R Hodgkin Lymphoma Three-year progression-free survival of 77%, including 91% after stem-cell transplantation Aug 23, 2021
Are Hemoglobin Cutoffs for Anemia Outdated? A growing call for WHO criteria to be tightened Aug 06, 2021
Woman Develops Tiny Blood Spots on Her Body After COVID Shot Case highlights need for quick diagnosis and management of rare disorder Aug 05, 2021
Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemia Complete responses in 18 of 20 patients with relapsed/refractory T-cell ALL Aug 04, 2021
Add-On Venetoclax Promising in Younger, Fit AML Patients "Safe and feasible intensive regimen" in small single-center study Jul 30, 2021
Call in the T-Cell Cavalry to Fight COVID in the Immunocompromised Preliminary research suggests immunotherapy could play role in protecting vaccine non-responders Jul 29, 2021
Shingrix OK'd for Immunocompromised Adults CDC's vaccine committee currently discussing vaccine for this population, manufacturer says Jul 26, 2021
Keytruda Before, After Surgery Improves Outcome in TNBC Results from KEYNOTE-522 show "practice-changing" impact on EFS Jul 15, 2021
